Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.470
-0.090 (-5.77%)
At close: Jun 27, 2025, 4:00 PM
1.470
0.00 (0.00%)
After-hours: Jun 27, 2025, 5:55 PM EDT
Aclaris Therapeutics Revenue
Aclaris Therapeutics had revenue of $1.46M in the quarter ending March 31, 2025, a decrease of -39.32%. This brings the company's revenue in the last twelve months to $17.78M, down -42.87% year-over-year. In the year 2024, Aclaris Therapeutics had annual revenue of $18.72M, down -40.09%.
Revenue (ttm)
$17.78M
Revenue Growth
-42.87%
P/S Ratio
7.45
Revenue / Employee
$277,766
Employees
64
Market Cap
159.17M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.72M | -12.53M | -40.09% |
Dec 31, 2023 | 31.25M | 1.50M | 5.03% |
Dec 31, 2022 | 29.75M | 22.99M | 340.05% |
Dec 31, 2021 | 6.76M | 279.00K | 4.30% |
Dec 31, 2020 | 6.48M | 2.26M | 53.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ACRS News
- 1 day ago - Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference - GlobeNewsWire
- 4 days ago - Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052 - GlobeNewsWire
- 4 weeks ago - Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewsWire
- 7 weeks ago - Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series - GlobeNewsWire
- 7 weeks ago - Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer - GlobeNewsWire
- 4 months ago - Aclaris Therapeutics to Participate in Two March Healthcare Conferences - GlobeNewsWire
- 4 months ago - New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3 - GlobeNewsWire